Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.

Bitter taste stimuli are detected by a diverse family of G protein-coupled receptors (GPCRs) expressed in gustatory cells. Each bitter taste receptor (TAS2R) responds to an array of compounds, many of which are toxic and can be found in nature. For example, human TAS2R16 (hTAS2R16) responds to β-glu...

Full description

Bibliographic Details
Main Authors: Tiffani A Greene, Suzanne Alarcon, Anu Thomas, Eli Berdougo, Benjamin J Doranz, Paul A S Breslin, Joseph B Rucker
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3101243?pdf=render
_version_ 1828931050039934976
author Tiffani A Greene
Suzanne Alarcon
Anu Thomas
Eli Berdougo
Benjamin J Doranz
Paul A S Breslin
Joseph B Rucker
author_facet Tiffani A Greene
Suzanne Alarcon
Anu Thomas
Eli Berdougo
Benjamin J Doranz
Paul A S Breslin
Joseph B Rucker
author_sort Tiffani A Greene
collection DOAJ
description Bitter taste stimuli are detected by a diverse family of G protein-coupled receptors (GPCRs) expressed in gustatory cells. Each bitter taste receptor (TAS2R) responds to an array of compounds, many of which are toxic and can be found in nature. For example, human TAS2R16 (hTAS2R16) responds to β-glucosides such as salicin, and hTAS2R38 responds to thiourea-containing molecules such as glucosinolates and phenylthiocarbamide (PTC). While many substances are known to activate TAS2Rs, only one inhibitor that specifically blocks bitter receptor activation has been described. Here, we describe a new inhibitor of bitter taste receptors, p-(dipropylsulfamoyl)benzoic acid (probenecid), that acts on a subset of TAS2Rs and inhibits through a novel, allosteric mechanism of action. Probenecid is an FDA-approved inhibitor of the Multidrug Resistance Protein 1 (MRP1) transporter and is clinically used to treat gout in humans. Probenecid is also commonly used to enhance cellular signals in GPCR calcium mobilization assays. We show that probenecid specifically inhibits the cellular response mediated by the bitter taste receptor hTAS2R16 and provide molecular and pharmacological evidence for direct interaction with this GPCR using a non-competitive (allosteric) mechanism. Through a comprehensive analysis of hTAS2R16 point mutants, we define amino acid residues involved in the probenecid interaction that result in decreased sensitivity to probenecid while maintaining normal responses to salicin. Probenecid inhibits hTAS2R16, hTAS2R38, and hTAS2R43, but does not inhibit the bitter receptor hTAS2R31 or non-TAS2R GPCRs. Additionally, structurally unrelated MRP1 inhibitors, such as indomethacin, fail to inhibit hTAS2R16 function. Finally, we demonstrate that the inhibitory activity of probenecid in cellular experiments translates to inhibition of bitter taste perception of salicin in humans. This work identifies probenecid as a pharmacological tool for understanding the cell biology of bitter taste and as a lead for the development of broad specificity bitter blockers to improve nutrition and medical compliance.
first_indexed 2024-12-14T00:41:02Z
format Article
id doaj.art-2cde677a705643af88a4a4ff10c2f7e6
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-14T00:41:02Z
publishDate 2011-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-2cde677a705643af88a4a4ff10c2f7e62022-12-21T23:24:22ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0165e2012310.1371/journal.pone.0020123Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.Tiffani A GreeneSuzanne AlarconAnu ThomasEli BerdougoBenjamin J DoranzPaul A S BreslinJoseph B RuckerBitter taste stimuli are detected by a diverse family of G protein-coupled receptors (GPCRs) expressed in gustatory cells. Each bitter taste receptor (TAS2R) responds to an array of compounds, many of which are toxic and can be found in nature. For example, human TAS2R16 (hTAS2R16) responds to β-glucosides such as salicin, and hTAS2R38 responds to thiourea-containing molecules such as glucosinolates and phenylthiocarbamide (PTC). While many substances are known to activate TAS2Rs, only one inhibitor that specifically blocks bitter receptor activation has been described. Here, we describe a new inhibitor of bitter taste receptors, p-(dipropylsulfamoyl)benzoic acid (probenecid), that acts on a subset of TAS2Rs and inhibits through a novel, allosteric mechanism of action. Probenecid is an FDA-approved inhibitor of the Multidrug Resistance Protein 1 (MRP1) transporter and is clinically used to treat gout in humans. Probenecid is also commonly used to enhance cellular signals in GPCR calcium mobilization assays. We show that probenecid specifically inhibits the cellular response mediated by the bitter taste receptor hTAS2R16 and provide molecular and pharmacological evidence for direct interaction with this GPCR using a non-competitive (allosteric) mechanism. Through a comprehensive analysis of hTAS2R16 point mutants, we define amino acid residues involved in the probenecid interaction that result in decreased sensitivity to probenecid while maintaining normal responses to salicin. Probenecid inhibits hTAS2R16, hTAS2R38, and hTAS2R43, but does not inhibit the bitter receptor hTAS2R31 or non-TAS2R GPCRs. Additionally, structurally unrelated MRP1 inhibitors, such as indomethacin, fail to inhibit hTAS2R16 function. Finally, we demonstrate that the inhibitory activity of probenecid in cellular experiments translates to inhibition of bitter taste perception of salicin in humans. This work identifies probenecid as a pharmacological tool for understanding the cell biology of bitter taste and as a lead for the development of broad specificity bitter blockers to improve nutrition and medical compliance.http://europepmc.org/articles/PMC3101243?pdf=render
spellingShingle Tiffani A Greene
Suzanne Alarcon
Anu Thomas
Eli Berdougo
Benjamin J Doranz
Paul A S Breslin
Joseph B Rucker
Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.
PLoS ONE
title Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.
title_full Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.
title_fullStr Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.
title_full_unstemmed Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.
title_short Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin.
title_sort probenecid inhibits the human bitter taste receptor tas2r16 and suppresses bitter perception of salicin
url http://europepmc.org/articles/PMC3101243?pdf=render
work_keys_str_mv AT tiffaniagreene probenecidinhibitsthehumanbittertastereceptortas2r16andsuppressesbitterperceptionofsalicin
AT suzannealarcon probenecidinhibitsthehumanbittertastereceptortas2r16andsuppressesbitterperceptionofsalicin
AT anuthomas probenecidinhibitsthehumanbittertastereceptortas2r16andsuppressesbitterperceptionofsalicin
AT eliberdougo probenecidinhibitsthehumanbittertastereceptortas2r16andsuppressesbitterperceptionofsalicin
AT benjaminjdoranz probenecidinhibitsthehumanbittertastereceptortas2r16andsuppressesbitterperceptionofsalicin
AT paulasbreslin probenecidinhibitsthehumanbittertastereceptortas2r16andsuppressesbitterperceptionofsalicin
AT josephbrucker probenecidinhibitsthehumanbittertastereceptortas2r16andsuppressesbitterperceptionofsalicin